www.diseases-diagnosis.com Homepage Diseases Symptoms Diseases Diagnosis Diseases Treatment Diseases Living Care Diseases Prevention Diseases Research
www
Search
March 26, 2016
Table of Contents

1 Introduction
BRCA1

Wikipedia

 

BRCA1 ( breast cancer 1, early onset, often ) is a human tumor suppressor gene, which produces a protein, called breast cancer type 1 susceptibility protein . It originally stood for Berkeley, California,

BRCA1 is expressed in the cells of breast and other tissue, where it helps repair damaged DNA, or destroy cells if DNA cannot be repaired. If BRCA1 itself is damaged, damaged DNA is not repaired properly and this increases risks for cancers.

The protein encoded by the BRCA1 gene combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC).




The human BRCA1 gene is located on the long (q) arm of chromosome 17 at band 21, from base pair 38,429,551 to base pair 38,551,283 (Build GRCh37/hg19) (map) . BRCA1 orthologs have been identified in most mammals for which complete genome data are available.




The BRCA1 protein ( breast cancer type 1 susceptibility protein also known as RING finger protein 53 ) contains the following domains:

  • Zinc finger, C3HC4 type ( RING finger )

  • BRCA1 C Terminus ( BRCT ) domain

This protein also contains nuclear localization signal and nuclear export signal motifs.




BRCA1 repairs double-strand breaks in DNA. The strands of the DNA double helix are continually breaking from damage. Sometimes one strand is broken, and sometimes both strands are broken simultaneously. BRCA1 is part of a protein complex that repairs DNA when both strands are broken. When both strands are broken, it's difficult for the repair mechanism to "know" how to replace the correct DNA sequence, and there are multiple ways to attempt the repair. The double-stranded repair mechanism that BRCA1 participates in is homologous recombination, in which the repair proteins utilize homologous intact sequence from a sister chromatid, homologous chromosome, or from the same chromosome (depending on cell cyle phase) as a template. This DNA repair takes place with the DNA in the cell nucleus, wrapped around the histone. Several proteins, including BRCA1, arrive at the histone-DNA complex for this repair.

In the nucleus of many types of normal cells, the BRCA1 protein interacts with RAD51 during repair of DNA double-strand breaks. These breaks can be caused by natural radiation or other exposures, but also occur when chromosomes exchange genetic material (homologous recombination, e.g. "crossing over" during meiosis). The BRCA2 protein, which has a function similar to that of BRCA1, also interacts with the RAD51 protein. By influencing DNA damage repair, these three proteins play a role in maintaining the stability of the human genome.

BRCA1 directly binds to DNA, with higher affinity for branched DNA structures. This ability to bind to DNA contributes to its ability to inhibit the nuclease activity of the MRN complex as well as the nuclease activity of Mre11 alone.

Transcription

BRCA1 was shown to co-purify with the human RNA Polymerase II holoenzyme in HeLa extracts, implying it is a component of the holoenzyme. SWI/SNF is a chromatin remodeling complex. Artificial tethering of BRCA1 to chromatin was shown to decondense heterochromatin, though the SWI/SNF interacting domain was not necessary for this role.

Other roles

Research suggests that both the BRCA1 and BRCA2 proteins regulate the activity of other genes and play a critical role in embryo development. The BRCA1 protein probably interacts with many other proteins, including tumor suppressors and regulators of the cell division cycle.




Certain variations of the BRCA1 gene lead to an increased risk for breast cancer. Researchers have identified hundreds of mutations in the BRCA1 gene, many of which are associated with an increased risk of cancer. Women who have an abnormal BRCA1 or BRCA2 gene have up to an 60% risk of developing breast cancer by age 90; increased risk of developing ovarian cancer is about 55% for women with BRCA1 mutations and about 25% for women with BRCA2 mutations.

These mutations can be changes in one or a small number of DNA base pairs (the building blocks of DNA). Those mutations can be identified with PCR and DNA sequencing.

In some cases, large segments of DNA are rearranged. Those large segments, also called large rearrangements, can be a deletion or a duplication of one or several exons in the gene. Classical methods for mutations detection(sequencing) are unable to reveal those mutations. Other methods are proposed: Q-PCR, Multiplex Ligation-dependent Probe Amplification (MLPA), and Quantitative Multiplex PCR of Shorts Fluorescents Fragments (QMPSF). New methods have been recently proposed: heteroduplex analysis (HDA) by multi-capillary electrophoresis or also dedicated oligonucleotides array based on comparative genomic hybridization (array-CGH).

Some results suggest that hypermethylation of the BRCA1 promoter , which has been reported in some cancers, could be considered as an inactivating mechanism for BRCA1 expression.

A mutated BRCA1 gene usually makes a protein that does not function properly because it is abnormally short. Researchers believe that the defective BRCA1 protein is unable to help fix mutations that occur in other genes. These defects accumulate and may allow cells to grow and divide uncontrollably to form a tumor.

BRCA1 mRNA 3' UTR can be bound by an miRNA, Mir-17 microRNA . It has been suggested that variations in this miRNA along with Mir-30 microRNA could confer susceptibility to breast cancer.

In addition to breast cancer, mutations in the BRCA1 gene also increase the risk of ovarian , fallopian tube and prostate cancers. Moreover, precancerous lesions ( dysplasia) within the Fallopian tube have been linked to BRCA1 gene mutations. Pathogenic mutations anywhere in a model pathway containing BRCA1 and BRCA2 greatly increase risks for a subset of leukemias and lymphomas.

Women who inherit a defective BRCA1 or BRCA2 gene have risks for breast and ovarian cancer that are so high and seem so selective that many mutation carriers choose to have prophylactic surgery. There has been much conjecture to explain such apparently striking tissue specificity. Major determinants of where BRCA1/2 hereditary cancers occur are related to tissue specificity of the cancer pathogen, the agent that causes chronic inflammation or the carcinogen. The target tissue may have receptors for the pathogen, become selectively exposed to an inflammatory process or to a carcinogen such as during digestion, metabolism or elimination. An innate genomic deficit in a tumor suppressor gene impairs normal responses and exacerbates the susceptibility to disease in organ targets. This theory also fits data for several tumor suppressors beyond BRCA1 or BRCA2. A major advantage of this model is that it suggests there may be some options in addition to prophylactic surgery.




All germ line BRCA1 mutations identified to date have been inherited, suggesting the possibility of a large ???founder??? effect in which a certain mutation is common to a well-defined population group and can theoretically be traced back to a common ancestor. Given the complexity of mutation screening for BRCA1, these common mutations may simplify the methods required for mutation screening in certain populations. Analysis of mutations that occur with high frequency also permits the study of their clinical expression. Additional examples of founder mutations in BRCA1 are given in Table 1 (mainly derived from ).

! BRCA1 mutation(s) !! Reference(s)
African-Americans 943ins10, M1775R
Ashkenazi Jewish 185delAG, 188del11, 5382insC
Austrians 2795delA, C61G, 5382insC, Q1806stop
Belgians 2804delAA, IVS5+3A>G
Dutch Exon 2 deletion, exon 13 deletion, 2804delAA
Finns 3745delT, IVS11-2A>G
French 3600del11, G1710X
French Canadians C4446T
Germans 5382insC
Greeks 5382insC
Hungarians 300T>G, 5382insC, 185delAG
Italians 5083del19
Japanese L63X, Q934X
Native North Americans 1510insG, 1506A>G
Northern Irish 2800delAA
Norwegians 816delGT, 1135insA, 1675delA, 3347delAG
Pakistanis 2080insA, 3889delAG, 4184del4, 4284delAG, IVS14-1A>G
Polish 300T>G, 5382insC, C61G, 4153delA
Russians 5382insC, 4153delA
Scottish 2800delAA
South Africans E881X
Spanish R71G
Swedish Q563X, 3171ins5, 1201del11, 2594delC




BRCA1 together with BRCA2 were patented in the United States by Myriad Genetics. On March 29, 2010, a coalition led by the American Civil Liberties Union (ACLU) successfully challenged the basis of Myriad???s patents in New York District Court. The patent has been invalidated, but the decision is being appealed.




BRCA1 has been shown to interact with

  • ABL1 ,

  • AKT1,

  • AR ,

  • ATR ,

  • ATM ,

  • ATF1,

  • AURKA ,

  • BACH1,

  • BARD1,

  • BRCC3,

  • BRE ,

  • BRIP1,

  • C-jun,

  • CHEK2,

  • CLSPN,

  • COBRA1 ,

  • CREBBP ,

  • CSNK2B,

  • CSTF2,

  • CDK2 ,

  • DHX9,

  • ELK4,

  • EP300,

  • ESR1 ,

  • FANCA,

  • FANCD2,

  • FHL2,

  • H2AFX,

  • JUNB,

  • JunD,

  • LMO4,

  • MAP3K3,

  • MED1,

  • MED17,

  • MED21,

  • MED24,

  • MRE11A,

  • MSH2,

  • MSH3,

  • MSH6,

  • Myc,

  • NBN ,

  • NMI ,

  • NPM1,

  • NCOA2 ,

  • NUFIP1,

  • P53,

  • POLR2A,

  • PPP1CA,

  • Rad50,

  • RAD51,

  • RBBP4,

  • RBBP7,

  • RBBP8,

  • RELA,

  • RB1 ,

  • RBL1 ,

  • RBL2 ,

  • RPL31,

  • SMARCA4

  • SMARCB1,

  • STAT1,

  • UBE2D1,

  • USF2,

  • VCP ,

  • XIST , and

  • ZNF350,




View a graphical representation of all GenBank isoforms at the UCSC Genome Browser

UCSC Gene details page




  • Breast cancer

  • Mary-Claire King








  • GeneReviews/NCBI/NIH/UW entry on BRCA1 and BRCA2 Hereditary Breast/Ovarian Cancer



This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "BRCA1".


Last Modified:   2010-11-25


Search
All informatin on the site is © www.diseases-diagnosis.com 2002-2011. Last revised: January 2, 2011
Are you interested in our site or/and want to use our information? please read how to contact us and our copyrights.
To let us provide you with high quality information, you can help us by making a more or less donation: